Sugi Predict

Sugi Predict / Compounds / Telotristat

Telotristat

Telotristat

SCHEMBL612369

Cc1ccn(-c2cc(Cl)ccc2[C@@H](Oc2cc(-c3ccc(CC(N)C(=O)O)cc3)nc(N)n2)C(F)(F)F)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TPH1TPH2

The experimentally established mechanism targets of Telotristat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPH1 known ✓ P17752 20/20 1.00
▸ TPH2 known ✓ Q8IWU9 5/20 1.00
▸ ADORA3 P0DMS8 2/20 1.00
▸ SLC6A2 P23975 2/20 1.00
▸ AGTR1 P30556 2/20 1.00
▸ SLC6A4 P31645 2/20 1.00
▸ CCKAR P32238 2/20 1.00
▸ SLC6A3 Q01959 2/20 1.00
▸ F2 P00734 1/20 1.00
▸ ESR1 P03372 1/20 1.00
▸ DRD1 P21728 1/20 1.00
▸ PTGS1 P23219 1/20 1.00
▸ PTGS2 P35354 1/20 1.00
▸ DRD3 P35462 1/20 1.00
▸ MLNR O43193 1/20 0.86
▸ NR3C1 P04150 1/20 0.86
▸ ADRA2B P18089 1/20 0.86
▸ ADRA2C P18825 1/20 0.86
▸ MC3R P41968 1/20 0.86
▸ HTR3A P46098 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Telotristat SCHEMBL612353 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
Telotristat SCHEMBL611625 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
Telotristat SCHEMBL611624 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
Telotristat SCHEMBL611626 1.00 TPH1 (1.00) TPH1TPH2ADORA3SLC6A2AGTR1
Telotristat SCHEMBL3654183 0.97 TPH1 (0.94) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL12527320 0.95 TPH1 (0.90) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL610573 0.94 TPH1 (0.89) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL610574 0.94 TPH1 (0.89) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL612946 0.94 TPH1 (0.89) TPH1TPH2ADORA3SLC6A2AGTR1
SCHEMBL19672627 0.94 TPH1 (0.89) TPH1TPH2ADORA3SLC6A2AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3808740-A1 ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TerSera Therapeutics LLC (US) 2021-04-21 — — EP claimed
US-20210008068-A1 SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE TERSERA THERAPEUTICS LLC 2021-01-14 — — US claimed
EP-3763374-A1 SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE Lexicon Pharmaceuticals, Inc. (US) 2021-01-13 — — EP claimed
EP-2753306-B1 SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE LEXICON PHARMACEUTICALS INC (US) 2020-09-23 — — EP claimed
US-20190000843-A1 SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE LEXICON PHARMACEUTICALS INC (US) 2019-01-03 — — US claimed
WO-2018150012-A1 AMORPHOUS FORM OF TELOTRISTAT ETIPRATE Esteve Química, S.A. (ES) 2018-08-23 — — WO claimed
EP-3363798-A1 AMORPHOUS FORM OF TELOTRISTAT ETIPRATE Esteve Química, S.A. (ES) 2018-08-22 — — EP claimed
EP-3318260-A1 METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS Lexicon Pharmaceuticals, Inc. (US) 2018-05-09 — — EP claimed
EP-2091940-B3 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS INC (US) 2017-12-06 — — EP claimed
EP-3176159-A1 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE Lexicon Pharmaceuticals, Inc. (US) 2017-06-07 — — EP claimed
EP-2203444-A1 SOLIDS FORMS OF ( S) -ETHYL 2-AMIN0-3- (4- (2 -AMINO- 6- ( (R) -1- (4-CHL0R0-2- O-METHYL-IH-PYRAZOL- 1-YL) PHENYL) -2, 2, 2-TRIFLUORETHOXY) -PYRIMIDIN-4-YL) PHENYL) PROPANOATE Lexicon Pharmaceuticals, Inc. (US) 2010-07-07 — — EP claimed
EP-2187887-A1 METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS Lexicon Pharmaceuticals, Inc. (US) 2010-05-26 — — EP claimed
US-7709493-B2 Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester LEXICON PHARMACEUTICALS, INC. (US) 2010-05-04 — — US claimed
US-20090286817-A1 Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester TERSERA THERAPEUTICS LLC 2009-11-19 — — US claimed
EP-2091940-A2 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE Lexicon Pharmaceuticals, Inc. (US) 2009-08-26 — — EP claimed
WO-2009042733-A1 SOLIDS FORMS OF ( S) -ETHYL 2-AMIN0-3- (4- (2 -AMINO- 6- ( (R) -1- (4-CHL0R0-2- O-METHYL-IH-PYRAZOL- 1-YL) PHENYL) -2, 2, 2-TRIFLUORETHOXY) -PYRIMIDIN-4-YL) PHENYL) PROPANOATE LEXICON PHARMACEUTICALS, INC. (US) 2009-04-02 — — WO claimed
US-20090088447-A1 SOLID FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)-PYRIMIDIN-4-YL)PHENYL)PROPANOATE AND METHODS OF THEIR USE TERSERA THERAPEUTICS LLC 2009-04-02 — — US claimed
WO-2009029499-A1 METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS LEXICON PHARMACEUTICALS, INC. (US) 2009-03-05 — — WO claimed
US-20090062540-A1 METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS LEXICON PHARMACEUTICALS, INC. 2009-03-05 — — US claimed
WO-2008073933-A2 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS, INC. (US) 2008-06-19 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286817-A1 Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester TPH1, TPH2, PAH TPH1 1/4885TPH2 2/4885ADORA3 364/4885
US-20210008068-A1 SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE TPP1, TPP2, TMPO TPH1 696/4885TPH2 709/4885ADORA3 3175/4885
US-20190000843-A1 SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE TPP1, TPP2, TMPO TPH1 696/4885TPH2 709/4885ADORA3 3175/4885
US-20090088447-A1 SOLID FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)-PYRIMIDIN-4-YL)PHENYL)PROPANOATE AND METHODS OF THEIR USE CPS1, TUBA3C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TPH1 2480/4885TPH2 2754/4885ADORA3 984/4885
US-20090062540-A1 METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS DPYD, TYMP, NUDT1 TPH1 754/4885TPH2 562/4885ADORA3 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.